EUVIMEDEUVIMED entdecken
Crossref

PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway

Qing Huang, Zhina Zhou, Lei Xu, Peng Zhan, Guangwei Huang

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Qing Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China. Hauptthemen laut MEDLINE: Smad3 Protein, Transforming Growth Factor beta1, Fibrosis, PCSK9 Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Health Commission of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progressive cardiac fibrosis, a hallmark of heart failure, remains poorly understood regarding Proprotein convertase subtilisin/kexin type 9 (PCSK9) 's role. This study aims to elucidate PCSK9's involvement in cardiac fibrosis. After ischemia/reperfusion (I/R) injury surgery in rats, PCSK9 inhibitors were used to examine their effects on the transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic 3 (Smad3) pathway and inflammation. Elevated PCSK9, TGF-β1, and Smad3 levels were observed in cardiac tissues post-I/R injury, indicating fibrosis. PCSK9 inhibition reduced pro-fibrotic protein expression, protecting the heart and mitigating I/R-induced damage and fibrosis. Additionally, it ameliorated cardiac inflammation and reduced post-myocardial infarction (MI) size, improving cardiac function and slowing heart failure progression. PCSK9 inhibitors significantly attenuate myocardial fibrosis induced by I/R via the TGF-β1/Smad3 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad3 ProteinTransforming Growth Factor beta1FibrosisPCSK9 InhibitorsRats, Sprague-DawleyMyocardial Reperfusion InjuryAnimalsRatsMaleSignal TransductionInflammationMyocardiumProprotein Convertase 9

Stichwörter der Autor:innen

Cardiac fibrosisInflammatory responseIschemia reperfusion injuryPCSK9TGF-β1/Smad3

Substanzen

Smad3 ProteinTransforming Growth Factor beta1Smad3 protein, ratPCSK9 InhibitorsPCSK9 protein, ratTgfb1 protein, ratProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China.
  • Department of Hematology, Anshun City People's Hospital, Anshun 561000, Guizhou, China.
  • Anshun Maternal and Child Health Care Hospital, Anshun 561000, Guizhou, China.
  • Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China. Electronic address: 419263483@qq.com.

Förderung

  • Health Commission of Guizhou Province

Zitieren

APA

Huang, Q., Zhou, Z., Xu, L., Zhan, P., & Huang, G. (2024). PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116563

Vancouver

Huang Q, Zhou Z, Xu L, Zhan P, Huang G. PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116563

BibTeX
@article{Huang2024,
  author = {Huang, Qing and Zhou, Zhina and Xu, Lei and Zhan, Peng and Huang, Guangwei},
  title = {PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116563}
}
Kostenlos starten →